Results 141 to 150 of about 2,897 (211)

Profiling of HCAR1 signalling reveals Gαi/o and Gαs activation without β‐arrestin recruitment and the discovery of an allosteric agonist

British Journal of Pharmacology, Volume 183, Issue 10, Page 2219-2235, May 2026.
Abstract Background and Purpose Lactate, historically viewed as a metabolic by‐product, has emerged as a signalling molecule via the G protein–coupled receptor Hydroxycarboxylic Acid Receptor 1 (HCAR1). The receptor is primarily expressed in adipocytes but also found in various other tissues.
Simon Lind, Shane C. Wright, Emilia Gvozdenovic, Kristina Nilsson, Kenneth L. Granberg, Michel Bouvier, Linda C. Johansson   +6 more
wiley   +1 more source

Advancing Pharmacoequity in Low‐ and Middle‐Income Countries via Model Informed Drug Development

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Across low‐ and middle‐income countries (LMICs) inequities in access to safe, effective medicines persist due to limited regulatory capacity, inadequate financing, and insufficient local data. Regulatory authorities are engaging with model‐informed drug development (MIDD), but uneven technical readiness and resource gaps limit uptake ...
Henry Enzama, Francis Williams Ojara, Ian S. Haworth, Sandra Cvijic, Catriona Waitt, Thaddeus H. Grasela   +5 more
wiley   +1 more source

Identification of Urinary Exosomal microRNAs Associated With Subclinical Acute T‐Cell‐Mediated Rejection in Kidney Transplant Recipients

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT This study aimed to evaluate the diagnostic utility of urinary exosomal microRNAs (miRNAs) in subclinical rejection following kidney transplantation by comparing miRNA expression profiles in urinary exosomes between patients with no evidence of rejection and patients with subclinical T‐cell‐mediated rejection (sc‐TCMR), as confirmed by ...
Soichiro Tajima, Miori Ono, Yuto Kawazoe, Hiroshi Noguchi, Tomohiro Shigematsu, Takashi Ogino, Shoji Nakamura, Takahiro Nakamura, Keizo Kaku, Takeshi Hirota, Ichiro Ieiri, Mayako Uchida   +11 more
wiley   +1 more source

Liver‐Specific Suppression of PLA2G6/iPLA2β Improves Glucose and Lipid Metabolism in High‐Fat Diet‐Fed Mice

The FASEB Journal, Volume 40, Issue 8, 30 April 2026.
Liver‐specific suppression of PLA2G6/iPLA2β by utilizing the short‐hairpin RNA knockdown technique using an adenovirus vector (Ad‐shPLA2G6) altered phospholipid and fatty acid metabolites and suppressed hepatic lipid accumulation, serum triglyceride, and fasting glucose levels.
Kahori Shimizu, Mana Nishibata, Katsuyuki Nagata, Sho Hori, Shotaro Michinaga, Miyuki Kanehara, Miho Hashimoto‐Iwasaki, Fuminori Sakurai, Hideo Shindou, Koji Tomita, Toru Nishinaka, Hiroyuki Mizuguchi   +11 more
wiley   +1 more source

Phase 2 trial of exercise and low‐dose ibuprofen for cancer‐related cognitive impairment in patients receiving chemotherapy

Cancer, Volume 132, Issue 8, 15 April 2026.
Abstract Background Interventions for cancer‐related cognitive impairment are understudied, particularly during therapy. Methods Patients with cancer receiving chemotherapy reporting cognitive problems were randomized to one of four study arms for 6 weeks in this phase 2 randomized controlled trial with a 2 × 2 factorial design.
Michelle C. Janelsins, Riham A. Alieldin, Tyler Holler, Hongying Sun, Po‐Ju Lin, Michelle Shayne, Alissa Huston, Kassandra Doyle, Michelle Porto, Mohamedtaki Tejani, Bryan Thompson, Allison Magnuson, Marcia Krebs, Richard F. Dunne, Supriya G. Mohile, Chin‐Shang Li, Umang Gada, Ajay Dhakal, Aram F. Hezel, Marcus S. Noel, Alok A. Khorana, Brian D. Yirinec, Nayana Kamath, David W. Dougherty, Tim A. Ahles, Gary R. Morrow, Karen M. Mustian   +26 more
wiley   +1 more source

Physiologically Based Biopharmaceutics Modeling (PBBM) to Evaluate the Biopredictive Power of Dissolution Methods for Rivaroxaban Tablets

The aim of this study was to use the physiologically based biopharmaceutics modeling (PBBM) strategy to evaluate the biopredictive power of different dissolution test conditions for immediate release tablets containing 20 mg of rivaroxaban. The model was developed and validated with literature data and used to predict plasma concentration-time curves ...
Eduardo Nabais de Carvalho Lauro, Bruna Wenyi Chuang Jou, Humberto Gomes Ferraz, Michele Georges Issa, Marcelo Dutra Duque   +4 more
openaire   +1 more source

Emerging perspectives on leveraging physiologically based biopharmaceutics modeling (PBBM) for BCS class III biowaivers: A webinar summary. [PDF]

J Pharm Sci
Fang L, Veerasingham S, Xu Y, Garcia-Arieta A, Kollipara S, Kanagasabapathy Y, Ahmed T, Martins FS, Suarez-Sharp S.   +8 more
europepmc   +1 more source

Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. [PDF]

Mol Pharm
Mackie C, Arora S, Seo P, Moody R, Rege B, Pepin X, Heimbach T, Tannergren C, Mitra A, Suarez-Sharp S, Borges LN, Kijima S, Kotzagiorgis E, Malamatari M, Veerasingham S, Polli JE, Rullo G.   +16 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery [PDF]

, 2015
Agnieszka Bienert, Damian Szczesny, Edmund Grześkowiak, Emilia Plenzler, Joanna Tyczka, Katarzyna Kut, Krzysztof Przybyłowski, Paweł Wiczling, Roman Kaliszan   +8 more
core   +1 more source

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025. [PDF]

CPT Pharmacometrics Syst Pharmacol
Cordes H, Annaert P, Balazki P, Benamara S, Bonan RH, Butler A, Chenel M, Cui Y, Dallmann A, de Witte WEA, Demeester C, Feick D, Gattacceca F, Geci R, Gerebtzoff G, Gruber A, Guimarães M, Hamadeh A, Hanke N, Ibarra M, Ince I, Kanacher T, Kuepfer L, Mil F, Montaseri G, Nauwelaerts N, Proenca S, Schaller S, Schlender JF, Schneider ARP, Sjögren E, Solodenko J, Staab A, Vrenken P, Troisi C, Teutonico D.   +35 more
europepmc   +1 more source